High-mix insulins

Concentrated insulins: the new basal insulins

INTRODUCTION Insulin therapy plays a critical role in the treatment of type 1 and type 2 diabetes mellitus. However, there is still a need to find basal insulins with 24-hour coverage and reduced risk of hypoglycemia. Additionally, with increasing obesity and insulin resistance, the ability to provide clinically necessary high doses of insulin at low volume is also needed. AREAS COVERED This ...

Animal Insulins - Current Status

There is no significant difference in the metabolic control with animal or human insulin. At present there is no clinical data comparing the diabetes related mortality and complications, with animal or human insulin. The earlier animal insulins were more immunogenic as compared to human insulin, but the present day highly purified monocomponent insulins are less antigenic and the difference in ...

Mix shifts toward high-demand implants.

Wearable Electronics & Big Data = High Volume, High Mix Smt!

With all the excitement around IoT (Internet of Things), big data and cognitive computing the impact of wearable electronics on the manufacturing environment frequently gets lost in the noise. However, the capability and capacity to serve the needs driven by these trends falls on the shoulders of the electronics industry and in particular SMT assembly. This paper explores the seemingly conflict...

Biosimilar insulins: a European perspective

Biosimilar insulins are likely to enter clinical practice in Europe in the near future. It is important that clinicians are familiar with and understand the concept of biosimilarity and how a biosimilar drug may differ from its reference product. The present article provides an overview of biosimilars, the European regulatory requirements for biosimilars and safety issues. It also summarizes th...